Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

Summary by MedPage Today
(MedPage Today) -- SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from the phase III PREVAIL...

2 Articles

MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

(MedPage Today) -- SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from the phase III PREVAIL...

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Anti-Aging, Acupuncture and Health News broke the news in on Monday, November 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Francisco, California icon

San Francisco, California

News
For You
SearchBlindspotLocal